Delirium at the End of Life

被引:16
作者
Agar, Meera [1 ]
Bush, Shirley H. [2 ,3 ,4 ,5 ]
机构
[1] Univ Technol Sydney, Fac Hlth, IMPACCT Improving Palliat Aged & Chron Care Clin, Bldg 10,Level 3,235 Jones St, Ultimo, NSW 2007, Australia
[2] Ottawa Hosp, Gen Campus,501 Smyth Rd,Box 206, Ottawa, ON K1H 8L6, Canada
[3] Bruyere Res Inst, 85 Primrose Ave, Ottawa, ON K1R 6M1, Canada
[4] Ottawa Hosp, Res Inst, 053 Carling Ave, Ottawa, ON K1Y 4E9, Canada
[5] Ottawa Hosp, Bruyere Continuing Care, Palliat Care, 43 Bruyere St, Ottawa, ON K1N 5C8, Canada
关键词
Delirium; Delirium pathophysiology; Delirium screening; Delirium prevention; Antipsychotics; Benzodiazepines; Palliative care; End of life; PALLIATIVE CARE; SUBSYNDROMAL DELIRIUM; ADVANCED CANCER; TERMINALLY-ILL; DEMENTIA; PLACEBO; HALOPERIDOL; VALIDATION; PREDICTORS; EFFICACY;
D O I
10.1016/j.mcna.2020.01.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Delirium is a prevalent acute neurocognitive condition in patients with progressive life-limiting illness. Delirium remains underdetected; a systematic approach to screening is essential. Delirium at the end of life requires a comprehensive assessment. Consider the potential for reversibility, illness trajectory, patient preference, and goals of care before proceeding with investigations and interventions. Management should be interdisciplinary, and nonpharmacologic therapy is fundamental. For patients with refractory and severe agitation or perceptual disturbance, judicious use of medication may also be required. Carers and family should be seen as partners in care and be involved in shared decision making about care.
引用
收藏
页码:491 / +
页数:12
相关论文
共 50 条
  • [31] Delirium in patients with cancer at the end of life
    Cobb, JL
    Glantz, MJ
    Nicholas, PK
    Martin, EW
    Paul-Simon, A
    Cole, BF
    Corless, IB
    [J]. CANCER PRACTICE, 2000, 8 (04) : 172 - 177
  • [32] The Trajectory of Terminal Delirium at the End of Life
    Chirco, Nahla
    Dunn, Karen S.
    Robinson, Sheria Grice
    [J]. JOURNAL OF HOSPICE & PALLIATIVE NURSING, 2011, 13 (06) : 411 - 418
  • [33] Delirium: non-pharmacological and pharmacological management
    Boland, Jason W.
    Lawlor, Peter G.
    Bush, Shirley H.
    [J]. BMJ SUPPORTIVE & PALLIATIVE CARE, 2019, 9 (04) : 482 - 484
  • [34] The Dilemma of Treating Delirium: the Conundrum of Drug Management
    Agar, Meera R.
    Amgarth-Duff, Ingrid
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (07) : 951 - 960
  • [35] Humanizing the Treatment of Hyperactive Delirium in the Last Days of Life
    Pandharipande, Pratik P.
    Ely, E. Wesley
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (11): : 1014 - 1015
  • [36] End-of-Life and Hospice Care in Neurologic Diseases
    Chou, Claudia Z.
    Everett, Elyse A.
    McFarlin, Jessica
    Ramanathan, Usha
    [J]. SEMINARS IN NEUROLOGY, 2024, 44 (05) : 523 - 533
  • [37] Improving the Management of Terminal Delirium at the End of Life
    Sutherland, Megan
    Pyakurel, Aakriti
    Nolen, Amy E.
    Stilos, Kalliopi
    [J]. ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING, 2020, 7 (04) : 389 - 395
  • [38] Single Question in Delirium (SQiD): testing its efficacy against psychiatrist interview, the Confusion Assessment Method and the Memorial Delirium Assessment Scale
    Sands, M. B.
    Dantoc, B. P.
    Hartshorn, A.
    Ryan, C. J.
    Lujic, S.
    [J]. PALLIATIVE MEDICINE, 2010, 24 (06) : 561 - 565
  • [39] Optimal goal of management of delirium in end-of-life cancer care
    Akechi, Tatsuo
    [J]. LANCET ONCOLOGY, 2020, 21 (07) : 872 - 873
  • [40] Dexmedetomidine Versus Midazolam for End-of-Life Sedationand Agitation:Protocol for a Randomized Controlled Trial (TheDREAMS Trial)
    Thomas, Benjamin
    Barclay, Greg
    Lo, Wing-Shan Angela
    Mullan, Judy
    Mansfield, Kylie
    [J]. JMIR RESEARCH PROTOCOLS, 2024, 13